Cyteir Therapeutics Stock Shares Outstanding
CYTDelisted Stock | USD 2.76 0.01 0.36% |
Cyteir Therapeutics fundamentals help investors to digest information that contributes to Cyteir Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyteir Stock. The fundamental analysis module provides a way to measure Cyteir Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyteir Therapeutics stock.
Cyteir |
Cyteir Therapeutics Company Shares Outstanding Analysis
Cyteir Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cyteir Therapeutics Shares Outstanding | 36 M |
Most of Cyteir Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyteir Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Cyteir Therapeutics has 36 M of shares currently outstending. This is 80.06% lower than that of the Biotechnology sector and 66.31% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 93.7% higher than that of the company.
Cyteir Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyteir Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyteir Therapeutics could also be used in its relative valuation, which is a method of valuing Cyteir Therapeutics by comparing valuation metrics of similar companies.Cyteir Therapeutics is currently under evaluation in shares outstanding category among its peers.
Cyteir Fundamentals
Return On Equity | -0.24 | |||
Return On Asset | -0.14 | |||
Current Valuation | (20.89 M) | |||
Shares Outstanding | 36 M | |||
Shares Owned By Insiders | 6.63 % | |||
Shares Owned By Institutions | 76.83 % | |||
Number Of Shares Shorted | 319.73 K | |||
Price To Earning | 0.36 X | |||
Price To Book | 0.87 X | |||
Gross Profit | (16.59 M) | |||
EBITDA | (33.41 M) | |||
Net Income | (33.22 M) | |||
Cash And Equivalents | 166.4 M | |||
Cash Per Share | 4.71 X | |||
Total Debt | 889 K | |||
Debt To Equity | 0.02 % | |||
Current Ratio | 19.95 X | |||
Book Value Per Share | 3.47 X | |||
Cash Flow From Operations | (25.79 M) | |||
Short Ratio | 3.07 X | |||
Earnings Per Share | (0.93) X | |||
Price To Earnings To Growth | (0.03) X | |||
Target Price | 3.0 | |||
Number Of Employees | 46 | |||
Beta | 0.096 | |||
Market Capitalization | 108.71 M | |||
Total Asset | 153.23 M | |||
Retained Earnings | (138.11 M) | |||
Working Capital | 143.89 M | |||
Current Asset | 834.8 M | |||
Current Liabilities | 366.9 M | |||
Net Asset | 153.23 M |
About Cyteir Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyteir Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyteir Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyteir Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |